Sanxin Medical announced that the company plans to use centralized bidding to repurchase some A-shares, and the repurchased shares will all be cancelled and the registered capital reduced. The total repurchase capital is not less than 30 million yuan and no more than 60 million yuan, and the repurchase price is no more than 13.86 yuan/share. Based on the upper limit of the repurchase price, the estimated number of shares to be repurchased is 2.164,500 to 4.329 million shares, accounting for 0.41%-0.83% of the company's total share capital. The repurchase implementation period is 12 months from the date the shareholders' meeting reviews and approves the repurchase plan. The repurchase plan still needs to be submitted to the company's shareholders' meeting for review and approval. As of the date of disclosure of the announcement, the company had not received plans from directors, supervisors, controlling shareholders and other relevant entities to reduce their holdings within the next six months.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.